Dr. Scott Baggett to Present Results at American Society of Pharmacognosy
EMERYVILLE, Calif., April 14 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) will present seminal information on a new drug candidate for the treatment of vaginal dryness at the 7th Annual Oxford International Conference on the Science of Botanicals & American Society of Pharmacognosy 4th Interim Meeting, April 12-16, 2008. Scott Baggett, Ph.D., a member of Bionovo's chemistry team, will present the structural elucidation of active estrogen receptor beta selective compounds from VG101, Bionovo's drug candidate for vaginal atrophy. This structural elucidation is key to the development of the drug candidate's mechanism of action and intellectual property protection.
The poster will describe the isolation and identification of a natural, selective estrogen receptor (ER) beta compound from VG101 and three synthetic derivatives. The presentation will detail the complete analysis of these compounds by Magnetic Resonance Imaging (MRI) and Liquid Chromatography with Mass Spectrometry Detection (LC/MS) analysis.
Dr. Rick Staub, Director of Chemistry at Bionovo stated, "This is an excellent example of our multidisciplinary approach to drug development. We integrate pharmacognosy, synthetic chemistry and cutting edge, physiologically relevant, biological assays to isolate and develop safe and efficacious pharmaceuticals. Here, we have isolated an isoflavonoid from VG101 and synthesized three analogues displaying selective estrogen receptor beta activity, which is the foundation of this drug candidate."
"More than 45% of menopausal women experience vaginal dryness, which,
untreated, can last for the rest of their lives," said Isaac Cohen,
|SOURCE Bionovo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved